Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms

Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22.

Authors

S K Balasubramanian¹, M Aly¹, Y Nagata¹, T Bat¹, B P Przychodzen¹, C M Hirsch¹, V Adema¹, V Visconte¹, T Kuzmanovic¹, T Radivoyevitch¹, A Nazha², S Mukherjee², M A Sekeres^{2

3}, J P Maciejewski¹

Affiliations

¹ Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA.
² Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
³ Department of Hematology and Medical Oncology, Leukemia Program, Cleveland Clinic, Cleveland, OH, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Aged
DNA (Cytosine-5-)-Methyltransferases / genetics*
DNA Methyltransferase 3A
Female
Humans
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / pathology
Male
Mutation / genetics*
Prognosis

Substances

DNMT3A protein, human
DNA (Cytosine-5-)-Methyltransferases
DNA Methyltransferase 3A

Grants and funding